Experion Holdings (EXP.V) has expanded into European markets by penning a LOI with a Polish import and distribution company to export medical flower to Poland for scientific purposes.

When companies reach a certain point in their growth trajectory, reaching out into new overseas markets for new opportunities makes good sense. The first international step for a North American cannabis company is usually into the European markets, including the Frankfurt Stock Exchange (which Experion is also now on as of today, incidentally), because it broadens the company’s exposure to international capital.

Conservative changes following well-worn paths to success rarely make headlines. They’re neither sexy nor sleek, but they also carry lower risk. They may not see the doubles that make small-cap investing so exciting, but they probably won’t go to zero either. In a market inundated with frothy promises and failure, that’s what makes Experion so interesting.

Incremental growth has been Experion’s modus operandi since inception.

Here’s what equity.guru’s Chris Parry had to say:

“While everyone else is losing tens of millions every quarter chasing shiny lights on the wall, paying crazy money for acquisitions that have no revenue, Garnett and Experion are just advancing what they have every day. A little more planted than yesterday. A little more harvested than yesterday. A new SKU here. A new customer there.”

Now into the European markets with an export deal.

The LOI has two parts.

The company will send medical flower products to Poland so the Polish company can implement testing and development procedures. The second part kicks in when the testing is finished, and Experion has a viable and established export and import channel between Canada and Poland.

The company will then increase exports of medical flower to Poland and build a stable, consistent revenue stream.

“The LOI represents a major milestone for Experion. As medical marijuana becomes more legalized around the world, Experion continues to focus on the vast export market in countries with early opportunities. By exporting products for scientific research, we are able to move past barriers to entry and be one of the first Canadian producers to enter Poland,” said Jay Garnett, CEO.

Again. Not sexy. This is a company that’s doing a lot of the same things other companies are doing.

But these things are mostly stepping stones. They’re developing, but while it’s important to know about them, it’s equally important to know where they’re going.

Here’s something else they’re doing:

Experion Holdings has provided an update on the company’s brands positioned to take advantage of Health Canada’s final regulations for value-add products (VAPs) such as cannabis topicals, edibles and extracts as well as Health Canada’s proposal to create a new category (cannabis health products) for therapeutic treatment of minor ailments such as sleeplessness or sore muscles or for use in pets, paving the way for a large new, untapped market.

Wait. There are lots of companies getting into edibles in December, but not many are getting on board with Health Canada’s cannabis health products line. Or therapeutic treatments for pets. At least not yet. There’s some new territory there for Experion to expand into something that nobody else is doing.

It’s almost like Experion’s incremental steps are leading up to something.

Only time will tell.

Experion Wellness’ stock price has risen slightly to $0.25.

The company also has 98,733,156 shares issued and outstanding and a market cap of $22.7 million.

—Joseph Morton

Full Disclosure: Experion Wellness is an Equity.Guru marketing client.